AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8138763 — intervention group
Group type: COMPARATOR
Intervention: Control group (no knowledge of serum cholesterol concentration)
Number of subjects: 495
Study 3273841 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal phenobarbital (700 mg loading dose, followed by daily maintenance until delivery)
Number of subjects: 39
Study 3273841 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phenobarbital)
Number of subjects: 39
Study 31481084 — intervention group
Group type: EXPERIMENTAL
Intervention: uCTX‐II levels
Number of subjects: 1241
Study 31481084 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX‐II levels
Number of subjects: 1241
Study 31481084 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone markers CTX‐I and osteocalcin
Number of subjects: 1241
Study 31481084 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker levels by gender
Number of subjects: 1241
Study 28346285 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt revascularization with percutaneous coronary intervention or coronary artery bypass grafting in addition to intensive medical therapy
Number of subjects: 2280
Study 28346285 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 2280
Study 25917166 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfect bonding/no gap
Number of subjects: 14
Study 25917166 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding material on dentin
Number of subjects: 14
Study 25917166 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding material on composite
Number of subjects: 14
Study 25917166 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (PB) on composite
Number of subjects: 14
Study 25917166 — intervention group
Group type: COMPARATOR
Intervention: No bonding material
Number of subjects: 14
Study 21621227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention called Managing Anxiety and Depression using Education and Skills (MADES)
Number of subjects: 100
Study 21621227 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 100
Study 19783802 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based intervention framed with psychological theory
Number of subjects: 778
Study 19783802 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 778
Study 16729379 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression tights
Number of subjects: 6
Study 16729379 — intervention group
Group type: COMPARATOR
Intervention: Elastic tights
Number of subjects: 6
Study 16729379 — intervention group
Group type: COMPARATOR
Intervention: Conventional shorts
Number of subjects: 6
Study 14673543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (88 mEq in 50 ml) administered as a slow bolus 1 hour prior to (201)Tl injection
Number of subjects: 8
Study 14673543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate intervention
Number of subjects: 8
Study 11782220 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 20
Study 11782220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9433652 — intervention group
Group type: EXPERIMENTAL
Intervention: grepafloxacin 600 mg after fasting or after consumption of a standard high-fat meal
Number of subjects: 16
Study 9433652 — intervention group
Group type: COMPARATOR
Intervention: grepafloxacin 400 mg alone or after infusion of famotidine 20 mg
Number of subjects: 16
Study 8499200 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg kg‐1
Number of subjects: 30
Study 8499200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 0.67 mg kg‐1
Number of subjects: 30
Study 8499200 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 0.1 mg kg‐1
Number of subjects: 30
Study 30544211 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal intervention with fish-oil capsules (215 mg DHA + 285 mg EPA)
Number of subjects: 360
Study 30544211 — intervention group
Group type: EXPERIMENTAL
Intervention: Child intervention with fish-oil-enriched complementary food (169 mg DHA + 331 mg EPA)
Number of subjects: 360
Study 30544211 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and child intervention
Number of subjects: 360
Study 30544211 — intervention group
Group type: COMPARATOR
Intervention: Maternal and child control
Number of subjects: 360
Study 28651304 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin and Propranolol combination therapy
Number of subjects: 64
Study 28651304 — intervention group
Group type: COMPARATOR
Intervention: Propranolol monotherapy
Number of subjects: 64
Study 26252195 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent rowers with LBP
Number of subjects: 10
Study 26252195 — intervention group
Group type: COMPARATOR
Intervention: Adolescent rowers without LBP
Number of subjects: 10
Study 23388270 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT use in cystic fibrosis management
Number of subjects: 0
Study 23388270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways Home for Respiratory Illness Project
Number of subjects: 0
Study 23388270 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing Self‐Efficacy for Self‐Management in People with Cystic Fibrosis
Number of subjects: 0
Study 23388270 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasmanian Community Fund Project (myCF pilot)
Number of subjects: 0
Study 21575884 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalazine with or without cholestyramine
Number of subjects: 54
Study 19738166 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab or Cetuximab (EGFR-targeted monoclonal antibodies)
Number of subjects: 0
Study 19738166 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutations
Number of subjects: 0
Study 19738166 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF or PIK3CA mutations or loss of PTEN expression
Number of subjects: 0
Study 16827066 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil and midazolam (RM group)
Number of subjects: 32
Study 16827066 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-ketamine-fentanyl (MKF group)
Number of subjects: 32
Study 12760990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl effect-site concentration of 0.8 ng/mL
Number of subjects: 50
Study 12760990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl effect-site concentration of 1.0 ng/mL
Number of subjects: 50
Study 12760990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl effect-site concentration of 1.4 ng/mL
Number of subjects: 50
Study 12760990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl effect-site concentration of 2.0 ng/mL
Number of subjects: 50
Study 12760990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl effect-site concentration of 3.0 ng/mL
Number of subjects: 50
Study 10998082 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (600 mg day‐1 for 5 days)
Number of subjects: 12
Study 10998082 — intervention group
Group type: COMPARATOR
Intervention: Exogenous NO (sodium nitroprusside)
Number of subjects: 12
Study 9417748 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin (7000 U bolus before PTCA, followed by 10,500 U infusion over 24 hours, then 3500 U s.c. twice a day for 28 days)
Number of subjects: 625
Study 9417748 — intervention group
Group type: COMPARATOR
Intervention: Control group (10,000 U unfractionated heparin bolus followed by 24,000 U infusion over 24 hours, then 28 days of s.c. placebo injections)
Number of subjects: 625
Study 9417748 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin
Number of subjects: 625
Study 9417748 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 625
Study 8171218 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin cream
Number of subjects: 40
Study 8171218 — intervention group
Group type: COMPARATOR
Intervention: Oxytetracycline cream
Number of subjects: 40
Study 3463571 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% chlorhexidine (CH) as the irrigating solution
Number of subjects: 11
Study 3463571 — intervention group
Group type: COMPARATOR
Intervention: Placebo as the irrigating solution
Number of subjects: 11
Study 30157388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (≤100 mg daily)
Number of subjects: 255
Study 30157388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 30157388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast
Number of subjects: 255
Study 26917604 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 40
Study 26917604 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 24614693 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich whole food supplement (blend of pomegranate, green tea, broccoli, and turmeric)
Number of subjects: 199
Study 24614693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 23512638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg (non-Chinese)
Number of subjects: 55
Study 23512638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg (Chinese)
Number of subjects: 55
Study 23512638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg (Chinese)
Number of subjects: 55
Study 23512638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (both doses in Chinese)
Number of subjects: 55
Study 23512638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (non-Chinese)
Number of subjects: 55
Study 20693186 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm for warfarin treatment
Number of subjects: 0
Study 20693186 — intervention group
Group type: COMPARATOR
Intervention: Clinical information only dosing algorithm for warfarin treatment
Number of subjects: 0
Study 18030007 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy prior to external beam radiation therapy
Number of subjects: 0
Study 18030007 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy prior to prostatectomy
Number of subjects: 0
Study 18030007 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy for 6 or 8 months prior to prostatectomy
Number of subjects: 0
Study 18030007 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy using docetaxel before prostatectomy
Number of subjects: 0
Study 15515187 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lidocaine
Number of subjects: 91
Study 15515187 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl
Number of subjects: 91
Study 15515187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study 11675332 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m² on days 1-5)
Number of subjects: 92
Study 11675332 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and prednisone (CAP; 750 mg/m² cyclophosphamide and 25 mg/m² doxorubicin on day 1 and 40 mg/m² prednisone on days 1-5)
Number of subjects: 92
Study 11675332 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 92
Study 11675332 — intervention group
Group type: COMPARATOR
Intervention: CAP
Number of subjects: 92
Study 11675332 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine and CAP
Number of subjects: 92
Study 9629509 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pancreatic enzyme treatment (Panzytrat, 20,000 units of lipase, 18,000 units of amylase, and 1000 units of protease per capsule, 18 capsules daily for 4 weeks)
Number of subjects: 12
Study 9629509 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 12
Study 9629509 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pancreatic enzyme treatment
Number of subjects: 12
Study 7931188 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment (n = 11)
Number of subjects: 17
Study 7931188 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched DNA (bDNA) assay
Number of subjects: 17
Study 7931188 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 17
Study 3364761 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with epinephrine (5 micrograms/ml)
Number of subjects: 30
Study 3364761 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine with epinephrine (5 micrograms/ml)
Number of subjects: 30
Study 3364761 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine (5 micrograms/ml)
Number of subjects: 30
Study 30318708 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent coaching
Number of subjects: 0
Study 30318708 — intervention group
Group type: COMPARATOR
Intervention: Control (no coaching)
Number of subjects: 0
Study 29452204 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐α (IFN) monotherapy or combination therapy of IFN and lamivudine (LAM)
Number of subjects: 69
Study 29452204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiviral therapy)
Number of subjects: 69
Study 27420093 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg resveratrol
Number of subjects: 36
Study 27420093 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg resveratrol
Number of subjects: 36
Study 27420093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24587636 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant streptokinase (rSK) 200000 IU, administered rectally every 6 hours for 48 hours.
Number of subjects: 220
Study 24587636 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine-based suppositories (0.25%), administered rectally up to a maximum of 5 days (20 suppositories).
Number of subjects: 220
Study 24587636 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant streptokinase (rSK)
Number of subjects: 220
Study 24587636 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine-based suppositories (0.25%)
Number of subjects: 220
Study 22592102 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF) for 6 months
Number of subjects: 100
Study 22592102 — intervention group
Group type: COMPARATOR
Intervention: Complementary foods with continued breastfeeding (CF)
Number of subjects: 100
Study 22592102 — intervention group
Group type: EXPERIMENTAL
Intervention: Total energy intake for EBF
Number of subjects: 100
Study 22592102 — intervention group
Group type: COMPARATOR
Intervention: Total energy intake for CF
Number of subjects: 100
Study 22592102 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (anthropometric outcomes, body composition)
Number of subjects: 100
Study 20580546 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed decision to participate (n = 155)
Number of subjects: 288
Study 20580546 — intervention group
Group type: COMPARATOR
Intervention: No informed decision to participate (n = 133)
Number of subjects: 288
Study 20580546 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate CT result (n = 64) with informed decision (n = 35)
Number of subjects: 288
Study 17135753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefatrizine (3 doses of 1 g every 12 hours)
Number of subjects: 20
Study 17135753 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 non-pregnant female volunteers)
Number of subjects: 20
Study 19807566 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 0
Study 19807566 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (general)
Number of subjects: 0
Study 12593550 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtympanic electrocochleography
Number of subjects: 40
Study 12593550 — intervention group
Group type: EXPERIMENTAL
Intervention: Extratympanic electrocochleography
Number of subjects: 40
Study 12593550 — intervention group
Group type: COMPARATOR
Intervention: Control group (age‐ and sex‐matched)
Number of subjects: 40
Study 10437748 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere) 100 mg/m2 every 3 weeks in neoadjuvant chemotherapy
Number of subjects: 20
Study 10437748 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin
Number of subjects: 20
Study 10437748 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-based induction chemotherapy
Number of subjects: 20
Study 8560051 — intervention group
Group type: EXPERIMENTAL
Intervention: lysine acetylsalicylate (1800 mg)
Number of subjects: 75
Study 8560051 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac (30 mg)
Number of subjects: 75
Study 8560051 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac (75 mg)
Number of subjects: 75
Study 1773955 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet
Number of subjects: 30
Study 1773955 — intervention group
Group type: COMPARATOR
Intervention: Polymeric diet
Number of subjects: 30
Study 6459262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 46
Study 6459262 — intervention group
Group type: COMPARATOR
Intervention: Carbon dioxide
Number of subjects: 46
Study 31784005 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawley retainer
Number of subjects: 77
Study 31784005 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainer
Number of subjects: 77
Study 31784005 — intervention group
Group type: COMPARATOR
Intervention: Private orthodontic practice
Number of subjects: 77
Study 31784005 — intervention group
Group type: EXPERIMENTAL
Intervention: Both retention protocols
Number of subjects: 77
Study 28950381 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-guided training
Number of subjects: 38
Study 28950381 — intervention group
Group type: COMPARATOR
Intervention: Textbook-guided training
Number of subjects: 38
Study 25946154 — intervention group
Group type: EXPERIMENTAL
Intervention: MosquiTRAP (MQT) mass trapping for 17 months
Number of subjects: 6
Study 25946154 — intervention group
Group type: COMPARATOR
Intervention: Control group (no traps)
Number of subjects: 6
Study 25946154 — intervention group
Group type: EXPERIMENTAL
Intervention: User satisfaction survey in intervention arm
Number of subjects: 6
Study 24026478 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress myocardial perfusion imaging (SMPI)
Number of subjects: 1508
Study 24026478 — intervention group
Group type: COMPARATOR
Intervention: Standard ED chest pain protocol (clinical assessment)
Number of subjects: 1508
Study 21298630 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser cyclophotocoagulation (DCPC)
Number of subjects: 40
Study 21298630 — intervention group
Group type: COMPARATOR
Intervention: Cyclocryotherapy (CCT)
Number of subjects: 40
Study 19740550 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Rehabilitation Treatment (SRT) + Computer‐aided Cognitive Remediation Treatment (CRT)
Number of subjects: 86
Study 19740550 — intervention group
Group type: COMPARATOR
Intervention: Standard Rehabilitation Treatment (SRT) + Placebo Training
Number of subjects: 86
Study 17785859 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 2
Study 17785859 — intervention group
Group type: COMPARATOR
Intervention: Natural exposure to malaria
Number of subjects: 2
Study 17785859 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 2
Study 15026791 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate 50 mg
Number of subjects: 564
Study 15026791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 11673605 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0
Study 11673605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9820262 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hydroxycitric acid (1500 mg per day)
Number of subjects: 135
Study 9820262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 7697476 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (Dolobid)
Number of subjects: 2
Study 7697476 — intervention group
Group type: EXPERIMENTAL
Intervention: Other nonsteroidal antiinflammatory drugs (aspirin, salsalate, salicylamide, lysine acetylsalicylate, acetaminophen, dipyrone, propyfenazone)
Number of subjects: 2
Study 2192696 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass (GBP)
Number of subjects: 16
Study 2192696 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical banded gastroplasty (VBG)
Number of subjects: 16
Study 2192696 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass (GBP) and Vertical banded gastroplasty (VBG)
Number of subjects: 16
Study 105164 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose continuous insulin infusion
Number of subjects: 18
Study 105164 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous bolus insulin
Number of subjects: 18
Study 31836995 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation as cholecalciferol vitamin D3 (50,000 I.U.) for 3 months
Number of subjects: 62
Study 31836995 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) without vitamin D supplementation for 3 months
Number of subjects: 62
Study 31528100 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir for 72 weeks
Number of subjects: 403
Study 31528100 — intervention group
Group type: COMPARATOR
Intervention: Control group (29 patients)
Number of subjects: 403
Study 28105515 — intervention group
Group type: EXPERIMENTAL
Intervention: Azosemide (long-acting loop diuretic)
Number of subjects: 288
Study 28105515 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (short-acting loop diuretic)
Number of subjects: 288
Study 26362541 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty
Number of subjects: 0
Study 26362541 — intervention group
Group type: COMPARATOR
Intervention: Topical medication (ocular hypotensive therapy)
Number of subjects: 0
Study 23237583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapregnancy non‐surgical periodontal treatment
Number of subjects: 99
Study 23237583 — intervention group
Group type: COMPARATOR
Intervention: Control group (deferred treatment until after delivery)
Number of subjects: 99
Study 20945744 — intervention group
Group type: COMPARATOR
Intervention: Combination bleaching with 38% and 9.5% hydrogen peroxide gels (G II)
Number of subjects: 60